IP Library Granted Patent US 11,672,872
Granted Patent B2
US 11,672,872 · App. 17/811,401 · Granted Jun 13, 2023

Anti-transferrin receptor antibody and uses thereof

Inventors: Romesh R. Subramanian (Framingham, MA); Mohammed T. Qatanani (Waltham, MA); Timothy Weeden (Waltham, MA); Cody A. Desjardins (Waltham, MA); Brendan Quinn (Boston, MA); John Najim (Waltham, MA)
Assignee: Dyne Therapeutics, Inc.
C07K16/2881A61K2039/505A61K2039/54C07K2317/24C07K2317/33C07K2317/55C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,672,872
App. No.
17/811,401
Filed
Jul 8, 2022
Granted
Jun 13, 2023
Kind
B2
Art Unit
1649
USPC
530/387.3
Abstract

Aspects of the disclosure relate to antibodies that bind to transferrin receptor (e.g., transferrin receptor 1) and complexes comprising the antibody covalently linked to a molecular payload. Methods of using the antibodies are also provided.

Claims (21)

1. An antibody that binds to human transferrin receptor (TfR), wherein the antibody is a Fab and comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 101 and a light chain comprising the amino acid sequence of SEQ ID NO: 90.

2. The antibody of claim 1 , wherein the heavy chain of the antibody comprises an N-terminal pyroglutamate.

3. The antibody of claim 1 , wherein the equilibrium dissociation constant (K D ) of binding of the antibody to the transferrin receptor is in a range from 10 −11 M to 10 −6 M.

4. The antibody of claim 1 , wherein the antibody does not specifically bind to the transferrin binding site of the transferrin receptor.

5. The antibody of claim 1 , wherein the antibody is cross-reactive with extracellular epitopes of a human and non-human primate transferrin receptor.

6. The antibody of claim 1 , wherein the antibody is not covalently linked to a molecular payload.

7. A composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

8. The composition of claim 7 , wherein the composition is suitable for intravenous administration.

9. The composition of claim 7 , wherein the composition is suitable for intravenous infusion.

10. The composition of claim 7 , wherein the composition is a sterile injectable solution.

11. A nucleic acid comprising nucleotide sequences encoding the heavy chain and/or the light chain of the antibody of claim 1 .

12. The nucleic acid of claim 11 , comprising a nucleotide sequence encoding the heavy chain of the antibody.

13. The nucleic acid of claim 11 , comprising a nucleotide sequence encoding the light chain of the antibody.

14. The nucleic acid of claim 11 , comprising a nucleotide sequence encoding the heavy chain and the light chain of the antibody.

15. The nucleic acid of claim 12 , wherein the nucleotide sequence is operably linked to a promoter.

16. The nucleic acid of claim 13 , wherein the nucleotide sequence is operably linked to a promoter.

17. The nucleic acid of claim 14 , wherein the nucleotide sequence is operably linked to a promoter.

18. A vector comprising the nucleic acid of claim 11 .

19. The vector of claim 18 , wherein the vector is an expression vector.

20. A cell comprising the vector of claim 18 .

21. The antibody of claim 1 , wherein the antibody is not covalently linked to an oligonucleotide.

Assignments (2)
SECURITY INTEREST Recorded Jun 27, 2025
From: DYNE THERAPEUTICS, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 071777/0300 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2022
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; WEEDEN, TIMOTHY; DESJARDINS, CODY A.; NAJIM, JOHN; QUINN, BRENDAN
To: DYNE THERAPEUTICS, INC.
Reel/Frame 062119/0222 →
Continuity (2)
Provisional Application 63220043 · Jul 9, 2021
Related Publication 20230051954A1 · Feb 16, 2023
Cited By (21)
US 12,239,716 US 12,239,717 US 12,263,225 US 12,280,122 US 12,319,743 US 12,325,753 US 12,329,824 US 12,329,825 US 12,357,703 US 12,370,264 US 12,397,062 US 12,403,203 US 12,428,487 US 12,440,574 US 12,440,575 US 12,460,011 US 12,478,687 US 12,496,352 US 12,624,120 US 12,662,545 US 12,697,394